Newly announced data from Eli Lilly’s Phase III BLAZE-1 clinical trial show a combination of two of the company’s monoclonal antibodies, bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016), significantly reduced the risk of hospitalization and death in high-risk patients with newly diagnosed coronavirus disease 2019.

Two weeks after AstraZeneca announced the company was withdrawing the use of Imfinzi as a treatment for bladder cancer in the United States, Swiss pharma giant Roche followed suit with the checkpoint inhibitor Tecentriq (atezolizumab).

Patients are asking to join clinical trials of antibody-based Covid-19 drugs after U.S. President Donald Trump was treated with an experimental therapy from Regeneron Pharmaceuticals Inc.

Vir Biotechnology and GlaxoSmithKline dosed the first patient in a Phase II/III clinical trial of VIR-7831, a fully human monoclonal antibody against Covid-19.

Eli Lilly is planning to seek another regulatory approval for Taltz after the medication hit the primary and secondary endpoints in a Phase III study for non-radiographic axial spondyloarthritis.

Humira’s dominance continues as the world’s top-selling prescription product as the biologic therapy is the first drug to exceed $20 billion in annual global sales.

PhaseBio Pharmaceuticals’ antiplatelet drug PB2452 received Breakthrough Therapy designation from the U.S. FDA.

Galapagos and MorphoSys signed an exclusive development and commercialization deal with Novartis for a drug compound being developed for the treatment of inflammatory diseases.

Daiichi Sankyo announced that its Phase III ENLIVEN trial of pexidartinib met its primary endpoint.

The European Commission approved Regeneron Pharmaceuticals’ and Sanofi’s key biologic treatment dupilumab for moderate-to-severe atopic dermatitis, the two companies said.